Pain
Recent clinical, regulatory, research and industry developments relating to this disease.
Pathology of pain and its implications for therapeutic interventions.
Brain-Derived Neurotrophic Factor, Nociception, and Pain.
From pain to tumor immunity: influence of peripheral sensory neurons in cancer.
Influence of Inflammatory Pain and Dopamine on Synaptic Transmission in the Mouse ACC.
Approval: Dzuveo (EMA)
Approval: PecFent (EMA)
Approval: Instanyl (EMA)
Approval: Effentora (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2027.
- 12 industry developments reported.
- Q1 2027A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
- Q1 2027The Efficacy of Ultrasound-guided Bilateral Superficial Cervical Plexus Block on Postoperative Pain Relief in Patients Undergoing Neck Surgeries, Prospective Randomized Controlled Study.
- Q3 2027Fficacy and Safety of Crisugabalin on Nociplastic Pain in Patients With Parkinson's Disease (RELIEF-PD): A Multicentre, Double-Blind, Randomised Controlled Trial
- Q3 2029Ultrasound-guided Erector Spinae Plane (ESP) Block Versus Trigger Point Injection (TPI) for Chronic Thoracic Myofascial Pain: A Randomized Controlled Trial
Clinical MilestonesView all 17Hide
- 2026-06-08Ultrasound-guided Erector Spinae Plane (ESP) Block Versus Trigger Point Injection (TPI) for Chronic Thoracic Myofascial Pain: A Randomized Controlled TrialResults expected Q3 2029
- 2026-05-18A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral NeuropathyResults expected Q1 2027
- 2026-04-23The Efficacy of Ultrasound-guided Bilateral Superficial Cervical Plexus Block on Postoperative Pain Relief in Patients Undergoing Neck Surgeries, Prospective Randomized Controlled Study.Results expected Q1 2027
- 2026-03-19Fficacy and Safety of Crisugabalin on Nociplastic Pain in Patients With Parkinson's Disease (RELIEF-PD): A Multicentre, Double-Blind, Randomised Controlled TrialResults expected Q3 2027
- 2026-07-31Efficacy of Perioperative Duloxetine in Patients at High Risk for Developing Chronic Postsurgical Pain After Inguinal Hernia Repair: a Multicenter Randomized Controlled Trial.Primary completion
- 2026-06-19Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty: A Blinded Randomized Controlled TrialCompleted
- 2026-05-15A Comparison Between Pregabalin and Acetaminophen for the Treatment of Post-Mastectomy Pain Syndrome: A Single-blinded Randomized Controlled TrialCompleted
- 2026-05-12Efficacy and Safety of Topical Lidocaine 23%/Tetracaine 7% Ointment Versus Placebo for Post-Hemorrhoidectomy Pain: A Double-Blind Randomized Controlled TrialCompleted
- 2026-05-05Etude randomisée contrôlée en Double-aveugle ESKAPE : ESKétamine Low-dose Versus kétamine Low-dose Pour la Douleur Aiguë sévère Aux Urgences, Comparaison Des Effets PsychodyslEptiquesCompleted
- 2027-05-30Effect of Dexmedetomidine Combined With Oseltamivir Fumarate for Patient-controlled Intravenous Analgesia Following Lobectomy in Patients With Nicotine DependenceWithdrawn
- 2027-01-01Steroids for Rhinoplasty: Pain, Nausea, Edema and EcchymosisWithdrawn
- 2026-12-01Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block for Postoperative Pain Control in Laparoscopic Cholecystectomy: Prospective Randomized Controlled Trial in Pediatric PatientsWithdrawn
- 2026-06-01Epidural Steroid Injection With Supplemental Oral Eplerenone for Low Back Pain: A Prospective, Double Blind Randomized TrialWithdrawn
- 2026-05-27Infiltration Between the Popliteal Artery and the Capsule of the Knee (iPACK) With Local Infiltration of Analgesia (LIA) and Adductor Canal Block (ACB) Improves Postoperative Pain in Total Knee Arthroplasty: A Randomized Controlled TrialTerminated
Industry & MarketView all 12Hide
- 2026-07-01Zimmer Biomet buys non-drug pain relief system from Pacira for up to $140MAcquisition · Fierce Biotech
- 2026-07-30Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain CandidateIndustry · GEN News
- 2026-07-29STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug JournavxIndustry · STAT News
- 2026-07-25A daily fiber supplement reduced knee arthritis pain and improved strengthIndustry · Science Daily
- 2026-07-17Why pain hurts more when we’re lonely, and the myth of original sin: Books in briefIndustry · Nature News
- 2027-05-30ClinicalEffect of Dexmedetomidine Combined With Oseltamivir Fumarate for Patient-controlled Intravenous Analgesia Following Lobectomy in Patients With Nicotine DependenceWithdrawn
- 2027-01-01ClinicalSteroids for Rhinoplasty: Pain, Nausea, Edema and EcchymosisWithdrawn
- 2026-12-01ClinicalEfficacy of Ultrasound-Guided Transversus Abdominis Plane Block for Postoperative Pain Control in Laparoscopic Cholecystectomy: Prospective Randomized Controlled Trial in Pediatric PatientsWithdrawn
- 2026-08-04IndustryLatigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s JournavxIndustry · Fierce Biotech
- 2026-07-31ClinicalEfficacy of Perioperative Duloxetine in Patients at High Risk for Developing Chronic Postsurgical Pain After Inguinal Hernia Repair: a Multicenter Randomized Controlled Trial.Primary completion
- 2026-07-30IndustryLatigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain CandidateIndustry · GEN News
- 2026-07-29IndustrySTAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug JournavxIndustry · STAT News
- 2026-07-25IndustryA daily fiber supplement reduced knee arthritis pain and improved strengthIndustry · Science Daily
- 2026-07-19IndustryLatigo preps IPO to fund non-opioid pain drug rival to Vertex’s JournaxIndustry · Fierce Biotech
- 2026-07-17IndustryBiotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain projectIndustry · Fierce Biotech
Clinical trials
The current development programme across all trial phases.
Evidence coverage
How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.
Largest gap: no meaningful change (56, trial-readability).
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Neoplasms2
- Pain2
- Adaptive Immunity1
- Affect1
- Angioplasty, Balloon, Coronary1
- Bone Neoplasms1
- Brain-Derived Neurotrophic Factor1
- Computer Simulation1
Leading journals6
- The Journal of neuroscience : the official journal of the Society for Neuroscience4
- International journal of molecular sciences3
- The Journal of clinical investigation3
- Frontiers in immunology2
- Journal of neuroinflammation2
- Advances in therapy1
Leading researchers8
- Liu F2
- Aiyegbusi OL1
- Andersson DA1
- Backus LR1
- Baharpoor A1
- Bair MJ1
- Bao T1
- Barton D1
Affiliations (unnormalised)6
- College of Medicine3
- School of Pharmacy2
- University Hospitals Birmingham NHS Foundation Trust2
- Aix-Marseille Université1
- American Society of Clinical Oncology1
- Birmingham Clinical Trials Unit1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Pain is an unpleasant sensation triggered by noxious stimuli detected by nerve endings of nociceptive neurons. It is a sensory experience that can vary substantially between individuals and can be influenced by both peripheral input and central modulation.
Pain is caused by activation of nociceptors by potentially damaging stimuli, including extremes of temperature and pressure and injury-related chemicals. The literature also supports pain arising or being amplified in association with opioid exposure, depression, and long COVID, but these are described as associated contexts rather than sole causes.
Pain begins when specialized peripheral sensory neurons transduce noxious stimuli into electrical signals that are relayed to higher brain centers. The literature also describes modulation through nociception, neuronal plasticity, signal transduction, synaptic transmission, excitatory postsynaptic potentials, and top-down central circuits, with shared biological pathways and neurotransmitters such as serotonin and inflammatory mediators including cytokines and tumor necrosis factor-alpha.
Factors associated with greater pain burden include depression, moderate to severe pain, impaired function, and refractory symptoms. Emotional state, anxiety, attention and distraction, past experiences, and memories can also enhance the pain experience, and opioid exposure is associated with opioid-induced hyperalgesia.
The grounding supports drug therapy as a general management modality, but does not specify a particular standard regimen. The literature also points to broader management of pain comorbidity and modulation, including approaches informed by neurotransmitter and inflammatory pathways, but not to a specific drug class as universal standard of care.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.